Altium Capital
VC Fund
New York, United States
Altium Capital is a healthcare investment firm focusing on the development of stage public mid-and small-cap equities. It focuses on identifying opportunities to invest in growth companies in the healthcare industry. Founded in 2017 by Jacob Gottlieb, Altium Capital is headquartered in New York.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Altium Capital invests in
Stages Altium Capital invests in
Countries Altium Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jacob Gottlieb
|
|||
|
Mark Gottlieb
|
|||
Investment Focus
Industry
- Biotechnology 10 (71%)
- Health Care 5 (36%)
- Therapeutics 5 (36%)
- Pharmaceutical 5 (36%)
- Biopharma 3 (21%)
Stage
- Post-IPO Equity 8 (57%)
- Series D 2 (14%)
- Seed 1 (7%)
- Series A 1 (7%)
- Funding Round 1 (7%)
Country
- United States 10 (71%)
- Canada 2 (14%)
- Israel 1 (7%)
- Australia 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jacob Gottlieb
CEO
|
CEO | Total investments: 0 | Find email | |
|
Mark Gottlieb
COO
|
COO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Quantum Brilliance
|
Quantum Brilliance builds room temperature quantum computers powered by synthetic diamond, enabling applications in everyday computing, including edge and massively parrellelized computing. | $20M / Series A / Jan 15, 2025 | |
Cybin
|
Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $150M / Post-IPO Equity / Mar 13, 2024 | |
Skye Bioscience
|
Skye Bioscience is a pharmaceutical company providing new therapeutic outcomes for diseases with significant prevalence and unmet needs. It develops proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions. | $50.3M / Post-IPO Equity / Jan 29, 2024 | |
Outlook Therapeutics
|
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development andtechnical excellence in order to create affordable medicines for patients around the world. | $65M / Post-IPO Equity / Jan 23, 2024 | |
Evogene
|
Evogene is an Ag-Biotech trait development company. The Company uses plant genomics and its technology platform to develop seed traits underlying crop performance and productivity. Evogene applies its technology through both biotechnology and breeding methods. | $8.5M / Post-IPO Equity / Jul 17, 2023 | |
Aligned
|
Aligned is a DeFi and Web3 infrastructure company. | $34M / Seed / Feb 24, 2022 | |
Renovacor
|
Renovacor is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease.Renovacor’s lead program is a recombinant adeno-associated virus (AAV)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associatedathanogene 3 (BAG3) gene.Dilated cardiomyopathy is a condition affecting over 3 million patients in the US and growing steadily. Many patients develop DCM due to ischemic heart disease. Recently subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM. One of these specific genes is the BAG3 gene. The prevalence of disease‑causing BAG3 haploinsufficiency is estimated at approximately 35,000 individuals in the United States, representing an orphan disease by FDA guidelines. It is estimated a similar number of DCM patients with BAG3 mutations exist in Europe. These patients are typically younger and progress to end-stage heart failure sooner than patients with ischemic heart disease. Currently, DCM patients with a BAG3 mutation are treated with standard of care for heart failure. Despite improvements in pharmacotherapy and care, the five‑year survival of a patient with DCM is only 50%. The development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent the progression of disease in this otherwise healthy population of young adults. | $30M / Post-IPO Equity / Sep 03, 2021 | |
Opus Genetics(formerly Ocuphire Pharma)
|
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $15M / Post-IPO Equity / Jun 08, 2021 | |
X4 Pharmaceuticals
|
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma(ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. | $55M / Post-IPO Equity / Mar 19, 2021 | |
Sagimet Biosciences
|
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $80M / Venture - Series Unknown / Feb 11, 2021 | |
| See all 14 investments → | |||
Co-Investors
Sphera Global Healthcare Fund
4 deals together
Google Ventures
3 deals together
Ikarian Capital
3 deals together
Acorn Bioventures
2 deals together
Affinity Asset Advisors
2 deals together
Axiom Associates
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Altium Capital invest in?
Altium Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series D stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Altium Capital?
Public channels for Altium Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Altium Capital?
The team at Altium Capital includes Jacob Gottlieb (CEO) and Mark Gottlieb (COO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
